1,4-dihydro-2,6-dimethyl-3-nitro-4-(2,1,3-benzoxadiazol-4-yl)pyridine-5-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶二唑类
• 英文名称: 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2,1,3-benzoxadiazol-4-yl)pyridine-5-carboxylic acid
• 英文别名: 4-(4-Benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3-nitro-5-pyridinecarboxylic；4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-5-nitro-1,4-dihydropyridine-3-carboxylic acid
• 化学式: C₁₄H₁₂N₄O₅
• 分子量: 316.273
• InChiKey: LNSOZIWDXPCSGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  134
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  1,4-dihydro-2,6-dimethyl-3-nitro-4-(2,1,3-benzoxadiazol-4-yl)pyridine-5-carboxylic acid 在 氯化亚砜 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  硝基氧烷基1,4-二氢-2,6-二甲基-3-硝基-4-（2,1,3-苯并恶二唑-4-基）吡啶-的合成，钙通道激动剂-拮抗剂的调节活性和一氧化氮的释放研究5-羧基外消旋物，对映异构体和非对映异构体。

  摘要：

  制备了一组新的杂化钙通道（CC）调节剂，其中异丙基1,4-二氢-2,6-二甲基-3-硝基-4-（2,1,3-苯并恶二唑-4-基）的异丙基酯部分吡啶5-羧基（PN 202-791）被各种一氧化氮（* NO）供体硝基氧基烷基酯取代基取代。在1,4-二氢吡啶环（1,4-DHP）的C-4位具有（R）构型的对映异构体或非对映异构体对豚鼠回肠纵向平滑肌（GPILSM）表现出更有效的体外CC拮抗剂活性），而不是具有（4S）-构型的化合物。硝基氧烷基化合物均未对GPILSM表现出禁忌的CC激动剂作用，该作用会引起平滑肌收缩。结构活性研究表明，对映异构体在1的C-4位置具有（S）-构型 在1,4-DHP环的C-4位置具有（4S）构型的4-DHP环或非对映异构体与（1R-）-1-甲基-2-硝基氧乙基酯取代基一起显示出最有效的豚鼠左心房（GPLA）的心脏CC激动剂（正性肌力）活性。这类化合物在体外释放* NO，

  DOI：

  10.1021/jm030333h

文献信息

• Synthesis and biological evaluation of 1,4-dihydropyridine calcium channel modulators having a diazen-1-ium-1,2-diolate nitric oxide donor moiety for the potential treatment of congestive heart failure
  作者：Carlos Velázquez、Edward E Knaus

  DOI：10.1016/j.bmc.2004.05.008

  日期：2004.7

  potent smooth muscle calcium channel antagonist activity (IC(50)'s in the 0.37-1.09 microM range) than related analogs having a C-4 3-pyridyl substituent (IC(50)'s=3.03-9.14 microM range) relative to the reference drug nifedipine (IC(50)=9.13 nM). The point of attachment of C-4 isomeric pyridyl substituents was a determinant of smooth muscle calcium channel antagonist activity where the relative potency

  一组具有一氧化氮供体O（2）-乙酰氧基甲基-1-（N-乙基-N-甲基氨基）或4的外消旋4-芳基（杂芳基）-1,4-二氢-2,6-二甲基-3-硝基吡啶-乙基哌嗪-1-基）重氮-1-1,2-二醇酸酯，通过偶联各自的4-芳基（杂芳基）-1,4-二氢-2,6-二甲基-3合成C-5酯取代基-硝基吡啶-5-羧酸与O（2）-乙酰氧基甲基-1- [N-（2-甲基磺酰氧基乙基）-N-甲基氨基]重氮-1-1,2-二醇酸酯或O（2）-乙酰氧基甲基-1- [4-（2-甲基磺酰氧基乙基）哌嗪-1-基]重氮-1-1,2-二醇盐。具有C-4 2-吡啶基，4-吡啶基，2-三氟甲基苯基或苯并呋喃山-4-基取代基的化合物显示出比在0.37-1.09 microM范围内更强的平滑肌钙通道拮抗剂活性（IC（50）在0.37-1.09 microM范围内）具有C-4 3-吡啶基取代基的相关类似物（IC（50）'s = 3.03-9。相对于参考药物硝苯地平为14
• Method of increasing satellite cell proliferation with an HDAC inhibitor
  申请人：PRESIDENT AND FELLOWS OF HARVARD COLLEGE

  公开号：US10660902B2

  公开（公告）日：2020-05-26

  The invention provides methods for inducing, enhancing or increasing satellite cell proliferation, and an assay for screening for a candidate compound for inducing, enhancing or increasing satellite cell proliferation. Also provided are methods for repairing or regenerating a damaged muscle tissue of a subject.

  本发明提供了诱导、增强或增加卫星细胞增殖的方法，以及用于筛选诱导、增强或增加卫星细胞增殖的候选化合物的检测方法。本发明还提供了修复或再生受试者受损肌肉组织的方法。
• Small molecules for mouse satellite cell proliferation
  申请人：President and Fellows of Harvard College

  公开号：US11026952B2

  公开（公告）日：2021-06-08

  The invention provides methods for inducing, enhancing or increasing satellite cell proliferation, and an assay for screening for a candidate compound for inducing, enhancing or increasing satellite cell proliferation. Also provided are methods for repairing or regenerating a damaged muscle tissue of a subject.

  本发明提供了诱导、增强或增加卫星细胞增殖的方法，以及用于筛选诱导、增强或增加卫星细胞增殖的候选化合物的检测方法。本发明还提供了修复或再生受试者受损肌肉组织的方法。
• DIRECTED DELIVERY OF AGENTS TO NEURAL ANATOMY
  申请人：Kramer Jeffery

  公开号：US20120310140A1

  公开（公告）日：2012-12-06

  The present invention is directed generally to systems, devices and methods for direct delivery of agents, e.g., pharmaceutical agents, to target spinal and neuronal anatomies, e.g., the dorsal root ganglia (DRG), for the treatment of various disorders, particularly pain and pain related disorders, such as chronic itch, sensory disorders, multiple sclerosis, post-herpetic neuralgia and the like. The system, devices and methods of the invention encompass the agents to be delivered to the target anatomy alone or in combination with electrical stimulation. The delivery device and systems and methods as disclosed herein place the distal end of the delivery element, which comprises at least one agent delivery structure, and optionally at least one electrode, in close proximity, or in contact with or next to the target spinal anatomy, e.g., DRG. A variety of agents can be delivered using the device, including sodium channel blockers, biologics, neuroinflammatory modulators, toxins etc., to selectively neuromodulate the neurons. Agent delivery and/or electrical stimulation can be automated and/or can be controlled automatically or by a pre-determined program, or by a patient control pump (PCA).
• CARDIAC GLYCOSIDES ARE POTENT INHIBITORS OF INTERFERON-BETA GENE EXPRESSION
  申请人：Ye Junqiang

  公开号：US20140088056A1

  公开（公告）日：2014-03-27

  The invention provides for a method of inhibiting interferon-beta gene expression and/or reducing the level of interferon-beta in a cell by contacting the cell with a Na + , Ca 2+ , or K + ion-channel modulator. The invention also provides for a method of treating a disease or disorder characterized by elevated interferon beta levels or elevated levels of interferon-beta gene expression. Additionally, the invention provides a method for treating pathogenic or non-pathogenic infections.